DEPLOYDatabase

Robot model

Epione

French medical robotics company developing the Epione robotic platform for CT-guided percutaneous tumor ablation, enabling minimally invasive treatment of…

Track Epione
Manufacturer
Quantum Surgical
Form factor
surgical
Maturity
commercial
Lifecycle
active
Deployments
6
Website
quantumsurgical.com ↗

The verified answer

As of Aug 2026, DEPLOY verifies Epione, a surgical by Quantum Surgical (commercial): 6 verified deployments on record. 1 source back the record.

Regulatory status1 FDA 510(k) clearance

Epione holds 1 FDA 510(k) clearance, per the DEPLOY registry.

See all 1 filings

Overview

French medical robotics company developing the Epione robotic platform for CT-guided percutaneous tumor ablation, enabling minimally invasive treatment of abdominal, lung, and bone cancers. Founded in 2017 by a team of former Medtech SA engineers led by Bertin Nahum, the company is headquartered in Montpellier with a US subsidiary in Miami. Now part of Precision IO Group after acquiring NeuWave Medical in February 2026, with over 1,400 patients treated across Europe and the United States.

Verified vs. claimed

Maturity stage
commercial(Commercially deployed with revenue-generating operations.)
Sources on file
View all sources →

Key facts

FDA cleared

abdominal ablation indication

CE marked

abdomen, chest, musculoskeletal

Acquired NeuWave Medical

Feb 2026

CEO

Bertin Nahum (President & Co-founder)

Group CEO

Kurt Azarbarzin (Precision IO Group, appointed Feb 2026)

Co-founders

Bertin Nahum, Fernand Badano, Lucien Blondel, Sophie Roca

Total funding

approx 90M USD (50M EUR equity + 30M EUR EIB loan)

FDA clearance

510(k) K223758 for abdominal tumor ablation

CE mark

abdomen, lung, and musculoskeletal indications

Parent company

Precision IO Group Inc. (since Feb 2026)

Patients treated

1400+ (as of 2026)

Data & sources

Web sources

1

1 source backing this record.View all →

Pricing

No verified price is on record for Epione. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

How DEPLOY tracks pricing

Deployments (6)

  • Epione at Leeds, UKoperational

    Leeds Teaching Hospitals NHS Trust acquired Epione, became fastest-adopting center with 25+ patients treated.

  • Epione at Londonoperational

    King's College Hospital NHS Foundation Trust became first UK hospital to adopt Epione.

  • Epione at Chicagooperational

    Rush University System for Health became first Midwest center to acquire Epione.

  • Epione at Marseille, Franceoperational

    Institut Paoli-Calmettes cancer center acquired Epione in March 2024.

  • Epione at Miamioperational

    First US patient treated at Baptist Health South Florida by Dr.

  • Epione at Villejuif, Franceoperational

    Gustave Roussy cancer center was the first hospital globally to adopt Epione.

Free to use on your site, with a link back to DEPLOY.

Epione on the deployment map

View the global map

Where Epione is verified operating. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Regulatory filings (1)

Safety record

1 recall and 1 incident on record (1 critical, 1 moderate). Most recent: Aug 2024.

critical
1
moderate
1
recall
1
fatality
1

Most recent: Aug 2024

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Incidents affecting Epione (2)

Includes incidents linked directly to this model or to deployments of it. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Sources (1)

  1. https://www.quantumsurgical.com/news/fda-clears-quantum-surgicals-epione-robot-for-all-abdominal-cancers

Common questions

What is Epione?
French medical robotics company developing the Epione robotic platform for CT-guided percutaneous tumor ablation, enabling minimally invasive treatment of abdominal, lung, and bone cancers. Founded in 2017 by a team of former Medtech SA engineers led by Bertin Nahum, the company is headquartered in Montpellier with a US subsidiary in Miami. Now part of Precision IO Group after acquiring NeuWave Medical in February 2026, with over 1,400 patients treated across Europe and the United States.
How much does Epione cost?
Epione's price is not publicly disclosed. DEPLOY has no verified price on record for Epione from Quantum Surgical. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is Epione actually deployed in the real world?
Yes. Epione is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Is Epione autonomous or teleoperated?
Not verified as fully autonomous. Epione's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (percutaneous needle insertion for tumor ablation), not independently confirmed to run without a human in the loop.
Who makes Epione?
Epione is made by Quantum Surgical, based in Montpellier, France, founded in 2017.
Where is Epione deployed?
6 verified deployments of Epione are on the DEPLOY registry, including at Leeds, UK, London, Chicago.
Can you buy Epione?
Epione is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
Is Epione FDA cleared?
Epione has 1 regulatory record on the DEPLOY registry: FDA 510(k) clearance, cleared. See the Regulatory filings section for each agency source.
What are alternatives to Epione?
On the DEPLOY registry, comparable surgical robots to Epione include Edison Histotripsy System, da Vinci (and Ion), Toumai, Stryker Mako SmartRobotics.
How does Epione compare to Edison Histotripsy System?
Epione and Edison Histotripsy System (HistoSonics · 14 deployments) are both surgical robots on the DEPLOY registry. Epione has 6 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
Is Epione a top surgical?
On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Epione ranks in roughly the top 25% of surgical models tracked by the registry.
What is Epione's maturity stage?
Epione is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
Is Epione safe?
Epione has 2 active incidents on record in the DEPLOY registry. 1 recall and 1 incident on record (1 critical, 1 moderate). Most recent: Aug 2024. Retracted incidents are excluded from this count.
What is the Epione surgical robot?
The Epione is an interventional oncology robot by Quantum Surgical that received FDA 510(k) clearance for commercial sale and use in treating early-stage liver cancer. The FDA later cleared Epione for all abdominal cancers. Epione enables precise, image-guided percutaneous ablation of tumors.
Quantum Surgical: Epione FDA 510(k) Quantum Surgical: Epione all abdominal cancers
Methodology: Verified · 1 source (no primary) · last reviewed 2026-07-12

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-07-12

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Epione.

Recent coverage

Epione in third-party press

Fire Erupts at MN Encampment Less Than a Week Before City Sweep

Aug 1, 2026

Quantum Surgical Acquires NeuWave Medical, Inc.

Feb 24, 2026

King's College Hospital Becomes First in United Kingdom to Adopt Epione

Jun 10, 2025